DA32 Life Science Tech Acquisition

General Information

We intend to capitalize on our management team’s background and experience to identify promising opportunities in the life sciences sector. We are offering Class A ordinary shares. (This is NOT a unit offering; most blank-check or SPAC IPOs are unit offerings.)

Our CEO is Steven Kafka, Ph.D., a managing partner at Section 32, a venture capital fund.

We are sponsored by Deerfield Management, ARCH Venture Partners and Section 32.

(Note: DA32 Life Science Tech Acquisition priced its SPAC IPO on July 27, 2021, in line with the terms in its prospectus: 20 million Class A ordinary shares at $10 each to raise $200 million.) 

Employees: 0
Founded: 2021
Contact Information
Address 345 Park Avenue South, 12th Floor New York, NY 10010, US
Phone Number (212) 551-1600
Web Address
View Prospectus: DA32 Life Science Tech Acquisition
Financial Information
Market Cap $256.5mil
Revenues $0 mil (last 12 months)
Net Income $0 mil (last 12 months)
IPO Profile
Symbol DALS
Exchange NASDAQ
Shares (millions): 20.0
Price range $10.00 - $10.00
Est. $ Volume $200.0 mil
Manager / Joint Managers J.P. Morgan/ Cowen and Company
CO-Managers -
Expected To Trade: 7/28/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change